Quick Answer
EXAGEN INC. reported Total Revenue of $66.58 million for fiscal year 2025.
EXAGEN INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $66.58M +19.7% |
$55.64M +5.9% |
$52.55M +15.3% |
$45.56M -5.7% |
$48.30M +15.1% |
$41.98M +3.9% |
| Revenue (ASC 606) | $66.58M +19.7% |
$55.64M +5.9% |
$52.55M +15.3% |
$45.56M -5.7% |
$48.30M +15.1% |
$41.98M +3.9% |
| Net Income | -$19.95M -32.0% |
-$15.12M +36.2% |
-$23.69M +50.0% |
-$47.39M -76.5% |
-$26.85M -60.9% |
-$16.69M -38.6% |
| Diluted EPS | -$0.93 -12.0% |
-$0.83 +38.1% |
-$1.34 +51.6% |
-$2.77 -64.9% |
-$1.68 -27.3% |
-$1.32 |
| Total Assets | $58.02M +29.8% |
$44.69M -21.5% |
$56.94M -34.0% |
$86.22M -30.2% |
$123.44M +57.5% |
$78.38M -11.3% |
| Cash and Equivalents | $32.22M +46.2% |
$22.04M -39.6% |
$36.49M -41.5% |
$62.39M -37.3% |
$99.44M +73.1% |
$57.45M -20.3% |
| Long-Term Debt | $22.26M +12.3% |
$19.82M +3.1% |
$19.23M -33.2% |
$28.78M +4.7% |
$27.48M +3.1% |
$26.66M +3.1% |
| Stockholders Equity | $17.45M +82.9% |
$9.54M -58.0% |
$22.69M -46.6% |
$42.46M -50.0% |
$84.94M +103.0% |
$41.84M -24.8% |
| R&D Expense | $6.25M +16.4% |
$5.38M +10.5% |
$4.87M -50.7% |
$9.88M +36.5% |
$7.24M +102.8% |
$3.57M +64.0% |
| Operating Income | -$14.07M -3.2% |
-$13.64M +40.3% |
-$22.84M +50.4% |
-$46.05M -91.3% |
-$24.07M -58.5% |
-$15.19M -63.3% |
| Gross Profit | $38.80M +17.2% |
$33.11M +12.4% |
$29.46M | — | — | — |
| Shares Outstanding | 22.91M +29.9% |
17.64M +3.5% |
17.05M +3.0% |
16.55M +2.4% |
16.16M +27.8% |
12.65M +0.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $17.24M | +37.9% | +0.2% |
| Revenue (ASC 606) | September 30, 2025 | $17.24M | +37.9% | +0.2% |
| Net Income | September 30, 2025 | -$7.09M | -41.0% | -59.7% |
| Diluted EPS | September 30, 2025 | -$0.31 | -10.7% | -47.6% |
| Total Assets | September 30, 2025 | $62.82M | +44.1% | +6.9% |
| Cash and Equivalents | September 30, 2025 | $35.65M | +61.8% | +18.7% |
| Long-Term Debt | September 30, 2025 | $22.26M | +12.3% | -0.2% |
| Stockholders Equity | September 30, 2025 | $18.14M | +41.0% | -13.8% |
| R&D Expense | September 30, 2025 | $1.73M | +16.8% | +16.7% |
| Operating Income | September 30, 2025 | -$3.10M | +33.5% | -17.9% |
| Gross Profit | September 30, 2025 | $10.07M | +44.3% | -3.1% |
| Shares Outstanding | September 30, 2025 | 22.51M | +28.5% | +2.3% |
- EXAGEN INC. reported Total Revenue of $66.58 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +19.7% in Total Revenue compared to the prior fiscal year.
- EXAGEN INC. reported Revenue (ASC 606) of $66.58 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +19.7% in Revenue (ASC 606) compared to the prior fiscal year.
- EXAGEN INC. reported Net Income of -$19.95 million for fiscal year 2025.
- EXAGEN INC. showed a decrease of -32.0% in Net Income compared to the prior fiscal year.
- EXAGEN INC. reported Diluted EPS of $0.93 per share (loss) for fiscal year 2025.
- EXAGEN INC. showed a decrease of -12.0% in Diluted EPS compared to the prior fiscal year.
- EXAGEN INC. reported Total Assets of $58.02 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +29.8% in Total Assets compared to the prior fiscal year.
- EXAGEN INC. reported Cash and Equivalents of $32.22 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +46.2% in Cash and Equivalents compared to the prior fiscal year.
- EXAGEN INC. reported Long-Term Debt of $22.26 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +12.3% in Long-Term Debt compared to the prior fiscal year.
- EXAGEN INC. reported Stockholders Equity of $17.45 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +82.9% in Stockholders Equity compared to the prior fiscal year.
- EXAGEN INC. reported R&D Expense of $6.25 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +16.4% in R&D Expense compared to the prior fiscal year.
- EXAGEN INC. reported Operating Income of -$14.07 million for fiscal year 2025.
- EXAGEN INC. showed a decrease of -3.2% in Operating Income compared to the prior fiscal year.
- EXAGEN INC. reported Gross Profit of $38.80 million for fiscal year 2025.
- EXAGEN INC. showed an increase of +17.2% in Gross Profit compared to the prior fiscal year.
- EXAGEN INC. reported Shares Outstanding of 22.91 million shares for fiscal year 2025.
- EXAGEN INC. showed an increase of +29.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: